CN105358985B - 靶向糖蛋白以治疗癌症的新方法 - Google Patents

靶向糖蛋白以治疗癌症的新方法 Download PDF

Info

Publication number
CN105358985B
CN105358985B CN201480036588.4A CN201480036588A CN105358985B CN 105358985 B CN105358985 B CN 105358985B CN 201480036588 A CN201480036588 A CN 201480036588A CN 105358985 B CN105358985 B CN 105358985B
Authority
CN
China
Prior art keywords
muc16
cells
antibody
cancer
akt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201480036588.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN105358985A (zh
Inventor
迈克尔·安东尼·霍林斯沃思
普拉卡什·拉达克里希南
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Nebraska System
Original Assignee
University of Nebraska System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Nebraska System filed Critical University of Nebraska System
Publication of CN105358985A publication Critical patent/CN105358985A/zh
Application granted granted Critical
Publication of CN105358985B publication Critical patent/CN105358985B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201480036588.4A 2013-07-09 2014-06-24 靶向糖蛋白以治疗癌症的新方法 Active CN105358985B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361844226P 2013-07-09 2013-07-09
US61/884,226 2013-07-09
PCT/US2014/043793 WO2015006043A1 (en) 2013-07-09 2014-06-24 Novel method of targeting glycoproteins to treat cancer

Publications (2)

Publication Number Publication Date
CN105358985A CN105358985A (zh) 2016-02-24
CN105358985B true CN105358985B (zh) 2018-08-28

Family

ID=52280458

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480036588.4A Active CN105358985B (zh) 2013-07-09 2014-06-24 靶向糖蛋白以治疗癌症的新方法

Country Status (5)

Country Link
US (1) US10023652B2 (https=)
EP (1) EP3019872A4 (https=)
JP (1) JP2016523961A (https=)
CN (1) CN105358985B (https=)
WO (1) WO2015006043A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2552959T (pt) 2010-03-26 2017-04-21 Memorial Sloan Kettering Cancer Center Anticorpos para muc16 e métodos de utilização dos mesmos
CN107667120B (zh) * 2015-03-17 2022-03-08 纪念斯隆-凯特林癌症中心 抗muc16抗体及其应用
CA3095457A1 (en) * 2018-05-09 2019-11-14 Quest Pharmatech Inc. Muc16 monoclonal antibody and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130059744A1 (en) * 2009-11-06 2013-03-07 Hans H. Wandall Method for early detection of cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005522483A (ja) * 2002-04-11 2005-07-28 アルタレックス メディカル コーポレーション 結合剤及び腫瘍細胞をターゲティングする際のそれらの使用
EP2144628B1 (en) * 2007-05-08 2012-10-17 Genentech, Inc. Cysteine engineered anti-muc16 antibodies and antibody drug conjugates
JP5686431B2 (ja) * 2011-01-28 2015-03-18 学校法人 京都産業大学 卵巣癌の検出方法、並びに、キット

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130059744A1 (en) * 2009-11-06 2013-03-07 Hans H. Wandall Method for early detection of cancer

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Birgit C. Schultes et al..Inducion of tomor- and CA125-specific T cell responses in patients(pts) with epithelial ovarian cancer(EOC) treated with OvaRex ® MAb-B43.13.《Proceedings of the American Association for Cancer Research》.2002,第43卷 *
Clinical development of Ovarex MAb-B43.13 monoclonal antibody for treatment of ovarian cancer: impact of immune responses and circulating CA125 levels on clinical efficacy;H.Fingert et al.;《European Journal of Cancer》;20010430;第37卷;S260 *

Also Published As

Publication number Publication date
CN105358985A (zh) 2016-02-24
EP3019872A1 (en) 2016-05-18
WO2015006043A1 (en) 2015-01-15
JP2016523961A (ja) 2016-08-12
EP3019872A4 (en) 2016-06-29
US20160376376A1 (en) 2016-12-29
US10023652B2 (en) 2018-07-17

Similar Documents

Publication Publication Date Title
Tsukamoto et al. Aminopeptidase N (APN)/CD13 inhibitor, Ubenimex, enhances radiation sensitivity in human cervical cancer
US11351255B2 (en) Treatment of cancer with therapeutic monoclonal antibody specific for a tumor associated antigen and an immune adjuvant
US9770482B2 (en) Targeting the EGFR-SGLT1 interaction for cancer therapy
CN105358985B (zh) 靶向糖蛋白以治疗癌症的新方法
Meng et al. Biomimetic nanomedicine targeting orchestrated metabolism coupled with regulatory factors to disrupt the metabolic plasticity of breast cancer
US11773183B2 (en) MUC16 monoclonal antibody and uses thereof
TW201517918A (zh) 癌症放射治療的增敏劑
CN103990127A (zh) 一种治疗肿瘤的药物组合物
WO2022192372A1 (en) Methods and compositions for tusc2 combination therapy with pdk1 inhibition
EP4611821A1 (en) Methods for the detection and treatment of non-small-cell lung cancer
WO2018141054A1 (en) Treatment of cancer with therapeutic monoclonal antibody specific for a tumor associated antigen and an immune adjuvant
US12343428B2 (en) Compositions and methods for cancer treatment
JP2022520287A (ja) 疾患の治療のための転写インヒビターと免疫チェックポイントインヒビターの組み合わせ
HK40012393A (en) Treatment of cancer with therapeutic monoclonal antibody specific for a tumor associated antigen and an immune adjuvant
US20230070306A1 (en) Monoclonal antibodies against her2/neu and uses thereof
WO2023021319A1 (en) Monoclonal antibodies against her2/neu and uses thereof
US20180120318A1 (en) Method of diagnosis of cancer and uses thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant